Amicus Therapeutics (FOLD) Upgraded to Strong-Buy at ValuEngine

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by investment analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a research note issued on Wednesday, May 2nd.

Several other brokerages have also commented on FOLD. BidaskClub upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, April 13th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 20th. Leerink Swann increased their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Cowen reissued a “buy” rating and issued a $22.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 10th. Finally, Robert W. Baird set a $20.00 price objective on Amicus Therapeutics and gave the company a “buy” rating in a report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $19.06.

Shares of Amicus Therapeutics traded up $0.31, reaching $16.87, during trading hours on Wednesday, Marketbeat.com reports. 56,244 shares of the company’s stock were exchanged, compared to its average volume of 2,991,427. Amicus Therapeutics has a 1 year low of $14.64 and a 1 year high of $15.59. The company has a quick ratio of 4.15, a current ratio of 4.21 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of -5.67 and a beta of 1.48.



Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. The company had revenue of $16.70 million for the quarter, compared to analysts’ expectations of $16.78 million. Amicus Therapeutics had a negative net margin of 563.98% and a negative return on equity of 60.09%. research analysts anticipate that Amicus Therapeutics will post -1.26 EPS for the current fiscal year.

In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of the firm’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $15.05, for a total value of $75,250.00. Following the completion of the sale, the insider now owns 90,409 shares of the company’s stock, valued at $1,360,655.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Daphne Quimi sold 8,149 shares of the firm’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $14.06, for a total value of $114,574.94. Following the completion of the sale, the senior vice president now directly owns 72,481 shares of the company’s stock, valued at approximately $1,019,082.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 126,899 shares of company stock valued at $1,875,875. Corporate insiders own 3.40% of the company’s stock.

Hedge funds have recently made changes to their positions in the company. Neuberger Berman Group LLC purchased a new position in shares of Amicus Therapeutics in the third quarter valued at $196,000. Palisade Capital Management LLC NJ purchased a new position in shares of Amicus Therapeutics in the first quarter valued at $211,000. Xact Kapitalforvaltning AB purchased a new position in shares of Amicus Therapeutics in the fourth quarter valued at $219,000. Cubist Systematic Strategies LLC purchased a new position in shares of Amicus Therapeutics in the third quarter valued at $231,000. Finally, Rockefeller Financial Services Inc. purchased a new position in shares of Amicus Therapeutics in the fourth quarter valued at $276,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply